drugset / Trial / NCT00271570

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

NCT00271570

RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the safety of infliximab in infants and children with acute Kawasaki Disease.

Timeline

Start
2004-04
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Immune Globulin Intravenous (Human) Protein / enzyme biologic 2 g/kg Intravenous
Subject Infliximab Monoclonal antibody 5 mg/kg Intravenous

Indications